Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs and broadening Orum’s global capabilities and operations
Orum Therapeutics, a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), announced that it secured 145 billion KRW in convertible preferred stock investments. This round is led by returning investor KB Investment and includes other existing investors, IMM Investment, Woori Venture Partners and Stassets Investment. New investors include Weiss Asset Management, a Boston-based global investment firm, and Korea Investment Partners, a major institutional venture investor with a strong track record in biotech investment. Additional new investors in this round are DSC Investment, Company K Partners, AON Investment, and DAYLI Partners.
Health Technology Insights: OrthAlign Expands Lantern Hip Platform for Posterior THA
“Our mission is to deliver degrader-antibody conjugate therapeutics that apply powerful degrader payloads with antibody-targeted precision to improve the treatment of cancer and other serious diseases,” said SJ Lee, Ph.D., Founder and CEO of Orum.
“Our mission is to deliver degrader-antibody conjugate therapeutics that apply powerful degrader payloads with antibody-targeted precision to improve the treatment of cancer and other serious diseases,” said Sung Joo (SJ) Lee, Ph.D., Founder and CEO of Orum. “This investment supports the next stage of our growth as we prepare to advance our next therapeutic programs towards clinical evaluation, develop additional novel payloads, and continue to build platforms that can generate differentiated drug candidates across oncology and beyond. We appreciate the confidence of both new and existing investors who share our commitment to delivering meaningful innovation for patients.”
Health Technology Insights: Solventum Wins Diamond HIRC Badge for Top Supply Chain Strength
This investment supports the advancement of ORM-1153 and additional programs in Orum’s pipeline and continued refinement of the Company’s DAC platforms, including development of additional novel payload classes beyond GSPT1. It also supports the expansion of Orum’s scientific and operational infrastructure as the Company advances additional targeted DAC programs based on principles of selectivity, potency, and rational payload design. These efforts are foundational to Orum’s strategy to generate differentiated therapeutic DAC programs for oncology and other serious diseases.
About Orum’s TPD Approach
Orum’s unique Dual-Precision Targeted Protein Degradation approach builds novel targeted protein degraders combined with the precise cell delivery mechanisms of antibodies to generate innovative, first-in-class, cell-selective TPDs for the treatment of cancer and other serious diseases. Orum has developed new targeted protein degrader payloads to specifically degrade an intracellular target protein within cancer cells via the E3 ubiquitin ligase pathway. Conjugated to antibodies, the payloads are designed to be delivered specifically to target cells and precisely degrade the intracellular target protein of interest.
Health Technology Insights: Ferronova Raises $6 Million to Boost Image-Guided Cancer Surgery
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
